Cronos Group, Inc. (CRON)
3.21
-0.02
(-0.62%)
USD |
NASDAQ |
Oct 12, 16:00
3.22
+0.01
(+0.31%)
After-Hours: 04:26
Cronos Group Price to Book Value : 1.114 for Oct. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 1.114 |
| October 09, 2026 | 1.120 |
| October 08, 2026 | 1.117 |
| October 07, 2026 | 1.124 |
| October 06, 2026 | 1.140 |
| October 05, 2026 | 1.127 |
| October 02, 2026 | 1.119 |
| October 01, 2026 | 1.114 |
| September 30, 2026 | 1.145 |
| September 29, 2026 | 1.172 |
| September 28, 2026 | 1.183 |
| September 25, 2026 | 1.159 |
| September 24, 2026 | 1.152 |
| September 23, 2026 | 1.180 |
| September 22, 2026 | 1.190 |
| September 21, 2026 | 1.155 |
| September 18, 2026 | 1.162 |
| September 17, 2026 | 1.169 |
| September 16, 2026 | 1.141 |
| September 15, 2026 | 1.110 |
| September 14, 2026 | 1.122 |
| September 11, 2026 | 1.089 |
| September 10, 2026 | 1.096 |
| September 09, 2026 | 1.094 |
| September 08, 2026 | 1.105 |
| Date | Value |
|---|---|
| September 04, 2026 | 1.131 |
| September 03, 2026 | 1.131 |
| September 02, 2026 | 1.124 |
| September 01, 2026 | 1.172 |
| August 31, 2026 | 1.169 |
| August 28, 2026 | 1.172 |
| August 27, 2026 | 1.176 |
| August 26, 2026 | 1.232 |
| August 25, 2026 | 1.218 |
| August 24, 2026 | 1.183 |
| August 21, 2026 | 1.148 |
| August 20, 2026 | 1.117 |
| August 19, 2026 | 1.141 |
| August 18, 2026 | 1.114 |
| August 17, 2026 | 1.093 |
| August 14, 2026 | 1.089 |
| August 13, 2026 | 1.096 |
| August 12, 2026 | 1.100 |
| August 11, 2026 | 1.068 |
| August 10, 2026 | 1.041 |
| August 07, 2026 | 1.075 |
| August 06, 2026 | 1.065 |
| August 05, 2026 | 0.9436 |
| August 04, 2026 | 0.9748 |
| August 03, 2026 | 0.9817 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Lexaria Bioscience Corp. | 1.140 |
| Target Group, Inc. (Canada) | -- |
| InMed Pharmaceuticals, Inc. | 6.755 |
| XORTX Therapeutics, Inc. | 0.5407 |
| NervGen Pharma Corp. | 15.12 |
Price to Book Value Related Metrics
| PE Ratio | 17.43 |
| PS Ratio | 6.831 |
| PEG Ratio | 0.0607 |
| Price to Free Cash Flow | 24.66 |
| Price | 3.21 |
| Earnings Yield | 5.74% |
| Market Cap | 1.190B |
| PEGY Ratio | 0.0607 |
| Normalized PE Ratio | 16.21 |